We have received text from H.R. 7336: ALS Better Care Act. This bill was received on 2026-02-03, and currently has 5 cosponsors.
Here is a short summary of the bill:
This bill, known as the ALS Better Care Act, aims to improve healthcare coverage for individuals diagnosed with amyotrophic lateral sclerosis (ALS) under the Medicare program. The key features of this proposed legislation include:
Coverage of ALS-Related Services
The bill seeks to amend the Social Security Act, specifically to add provisions that would provide coverage for a variety of services related to ALS. These services include:
- Specialized physician or nurse practitioner support
- Occupational therapy support
- Speech pathology support
- Physical therapy
- Dietary support
- Respiratory support
- Registered nurse support
- Coordination of durable medical equipment
These services are viewed as essential for managing the complex medical needs of ALS patients. Accessibility to these services is expected to lead to improved patient outcomes and longer lifespans.
Payment System for ALS-Related Services
The legislation proposes a payment system that would provide a single payment amount for ALS-related services furnished during a patient visit. The initial payment amount is set at $800 for 2027, with annual adjustments based on market changes in subsequent years. The system also includes incentives for providers participating in ALS clinical trials to cover additional costs incurred during those trials.
No Cost Sharing
Under this bill, ALS-related services would be covered without any cost-sharing requirements for the patient. This means patients would not have to pay co-pays or deductibles for these services.
Telehealth Provisions
The bill emphasizes the importance of telehealth services for ALS patients, especially for those in rural or underserved areas. The legislation aims to ensure that remote medical management options are part of the care available to ALS patients, facilitating access to necessary services without the burden of traveling long distances.
Challenges in Clinical Trials
The bill mandates a report from the Secretary of Health and Human Services to identify challenges related to the administration and staffing of clinical trials for ALS. The report is intended to outline actionable steps to address these challenges and may include legislative recommendations for further improvement.
Implementation and Future Recommendations
The bill provides for the Secretary of Health and Human Services to implement these provisions, either through program instructions or formal rulemaking processes. Furthermore, it establishes a system for recommending ongoing adjustments in payment amounts based on evolving needs and costs associated with ALS-related services.
Relevant Companies
- AMGN (Amgen Inc.): This biotechnology company engages in the development and commercialization of therapies, including those for neuromuscular diseases such as ALS. Improved reimbursement for ALS-related care may enhance their market opportunities.
- BIIB (Biogen Inc.): This biopharmaceutical company specializes in therapies for neurological diseases and may see increased demand for research and therapies related to ALS as a result of enhancements in Medicare coverage.
- REGN (Regeneron Pharmaceuticals): Specializes in developing biopharmaceuticals for various medical needs, including neurological drugs. Increased funding and coverage for ALS treatment could open avenues for expanded research and treatment options.
Representative Janice D. Schakowsky Bill Proposals
Here are some bills which have recently been proposed by Representative Janice D. Schakowsky:
- H.R.7336: ALS Better Care Act
- H.R.7023: To amend the Patient Protection and Affordable Care Act to establish a public health insurance option, and for other purposes.
- H.R.6818: To extend protections to part-time workers in the areas of family and medical leave and to ensure equitable treatment in the workplace.
- H.R.6594: Medical Device Recall Improvement Act of 2025
- H.R.6116: Safe Hydration is an American Right in Energy Development Act of 2025
- H.R.5605: Medical Device Nonvisual Accessibility Act of 2025
You can track bills proposed by Representative Janice D. Schakowsky on Quiver Quantitative's politician page for Schakowsky.
Representative Janice D. Schakowsky Net Worth
Quiver Quantitative estimates that Representative Janice D. Schakowsky is worth $586.0K, as of March 5th, 2026. This is the 384th highest net worth in Congress, per our live estimates.
Schakowsky has approximately $0 invested in publicly traded assets which Quiver is able to track live.
You can track Representative Janice D. Schakowsky's net worth on Quiver Quantitative's politician page for Schakowsky.
2026 Illinois's 9th Congressional District Election
There has been approximately $19,348,651 of spending in Illinois's 9th congressional district elections over the last two years, per our estimates.
Approximately $5,733,928 of this has been from outside spending by PACs and Super PACs. Some of the groups who are spending money in this race include:
- ELECT CHICAGO WOMEN AKA ECW ($4,212,015)
- EDW ACTION FUND ($500,345)
- 314 ACTION FUND ($409,810)
- CONGRESSIONAL PROGRESSIVE CAUCUS PAC ($389,257)
- CHICAGO PROGRESSIVE PARTNERSHIP ($165,500)
The rating for this race is currently "Solid D".
You can track this election on our matchup page for the 2026 Illinois's 9th congressional district election.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
